The Scientific Data Management market is in need of new solutions to meet the current informatics challenges resulting from shifts toward externalization, biologics and precision medicine initiatives. Historical approaches to data management have hit plateaus in value, as the lack of flexibility in legacy system architectures have required large amounts of custom code to deal with the rapid pace and change of scientific innovation.
Our observations from recent customer experiences along with many others in the ten years since our inception has taught us that the life science industry is being subjected to its own Nexus of Forces. The Core Platform is evolving to harness the Nexus of Forces impacting your businesses.
- Biologics — Drug Discovery programs are being shifted to biologics from small molecules.
- Externalization — Businesses are accelerating investments in externalization and contract research.
- Precision Medicine — Next Generation Sequencing technology is enabling targeted therapies & precision medicine initiatives.
- Harmonization — A heightened emphasis on decreasing complexity in R&D by harmonizing laboratory workflows and cross functional collaboration.
Many biopharma companies are engaged in collaborations with CROs, academia or other biopharma companies. This means more and more of their most important data and results required to drive decisions are being generated outside the firewall. Most legacy vendor and home grown solutions cannot be deployed beyond corporate networks to manage these relationships or the data they produce. As a result, this data is being exchanged via SharePoint sites which are void of any scientific context, email or even sent snail mail.
We recognized this shift in the market and have been supporting customers operating under this model for over five years.
One of the forces influencing rapid change in the life sciences, is the shift toward biologics. Fifteen years ago, none of the top ten drugs were antibodies and just one was a protein. Last year, five antibodies and two recombinant proteins lead the top ten drugs list with only three small molecules remaining.
Another force influencing the life sciences is the shift toward precision medicine initiatives. A recent McKinsey report identifies significant opportunities and an unmet need for targeted therapies in lung, breast, colorectal and prostate cancer. Advances in Next-Gen Sequencing technology is now empowering biopharmaceutical companies with new tools to understand the molecular underpinning for these diseases, and to identify novel targets for their treatment. In fact, according to this report 53 different targeted therapies are currently in various stages of clinical development.
And to bring these new drugs to market, biopharmas are partnering with NGS technology vendors to provide companion diagnostics which directly align to the same genotype as the targeted therapy.
Most of the large pharmaceutical organizations we work with require unique solutions to migrate from, or integrate with, complex legacy infrastructures that are not only comprised of legacy vendor products but more commonly home-grown systems. These customers selected us over other point solutions, as they saw an opportunity to decrease complexity and expense while accelerating time to value and beginning to harmonize and optimize processes on a single cloud ready platform.
The flexibility of Platform for Science software enables it to rapidly conform to the existing data models and data structures established by legacy infrastructure, but this flexibility is not the complete solution. Other areas of investment include the SDK and OData compliance in the API.
Core’s Jobs Framework has grown to become a very important part of how our platform can orchestrate synchronization routines with legacy applications to data integrity across systems. Triggers, which provide access to our event model, have also evolved to now offer configured notifications via email, file systems and web services.
We will soon offer configured integrations to a multitude of enterprise software applications as OData provides native compatibility with most enterprise service bus technologies.
Everything is changing and Core is providing solutions to meet these growing and largely un-met informatics needs – today and tomorrow.